Literature DB >> 16236123

HLA Class II molecules on haplotypes associated with type 1 diabetes exhibit similar patterns of binding affinities for coxsackievirus P2C peptides.

Richard J Ellis1, Ruben Varela-Calvino, Timothy I M Tree, Mark Peakman.   

Abstract

Enteroviruses such as coxsackievirus B4 (CVB4) are proposed as possible environmental triggers or accelerants of the autoimmune process that leads to type 1 diabetes mellitus. One putative mechanism to account for this association is mimicry between virus components and islet autoantigens. Particular interest has focused on the CVB4 non-structural protein P2C, which we previously showed to be a major target of the effector memory anti-CVB4 CD4 T-cell response, and which harbours a region of sequence similarity with the islet autoantigen, glutamic acid decarboxylase (GAD65). Since several distinct human leucocyte antigen (HLA) Class II molecules are associated with development of type 1 diabetes, we hypothesized that for functional mimicry to be important, any potential region(s) of mimicry in P2C should bind to each of these susceptibility molecules. In the present study therefore we examined the affinity of 20-mer overlapping P2C peptides for soluble HLA-DR4, -DR3, -DQ2 and -DQ8. We identified one discrete region of P2C with high binding affinities for all of these HLA Class II molecules. Moreover, the binding affinity of P2C peptides was significantly correlated between HLA molecules present on the same susceptibility haplotype (e.g. DR4 and DQ8, P =0.0076; DR3 and DQ2 P = 0.002). We conclude that possession of these haplotypes favours restricted presentation of viral epitopes, and speculate that this could promote the potential for mimicry between microbial proteins and islet autoantigens.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16236123      PMCID: PMC1802420          DOI: 10.1111/j.1365-2567.2005.02233.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  41 in total

1.  ProPred: prediction of HLA-DR binding sites.

Authors:  H Singh; G P Raghava
Journal:  Bioinformatics       Date:  2001-12       Impact factor: 6.937

Review 2.  Enteroviruses and type 1 diabetes.

Authors:  Ruben Varela-Calvino; Mark Peakman
Journal:  Diabetes Metab Res Rev       Date:  2003 Nov-Dec       Impact factor: 4.876

3.  Prediction of MHC class I binding peptides using profile motifs.

Authors:  Pedro A Reche; John-Paul Glutting; Ellis L Reinherz
Journal:  Hum Immunol       Date:  2002-09       Impact factor: 2.850

4.  Promiscuous binding of proinsulin peptides to Type 1 diabetes-permissive and -protective HLA class II molecules.

Authors:  T P Astill; R J Ellis; S Arif; T I M Tree; M Peakman
Journal:  Diabetologia       Date:  2003-04-09       Impact factor: 10.122

5.  The use of relative operating characteristic (ROC) curves in test performance evaluation.

Authors:  J R Beck; E K Shultz
Journal:  Arch Pathol Lab Med       Date:  1986-01       Impact factor: 5.534

6.  Enterovirus infections are associated with the induction of beta-cell autoimmunity in a prospective birth cohort study.

Authors:  Kimmo Salminen; Karita Sadeharju; Maria Lönnrot; Paula Vähäsalo; Antti Kupila; Sari Korhonen; Jorma Ilonen; Olli Simell; Mikael Knip; Heikki Hyöty
Journal:  J Med Virol       Date:  2003-01       Impact factor: 2.327

7.  Characterization of the T-cell response to coxsackievirus B4: evidence that effector memory cells predominate in patients with type 1 diabetes.

Authors:  Ruben Varela-Calvino; Richard Ellis; Gianluca Sgarbi; Colin M Dayan; Mark Peakman
Journal:  Diabetes       Date:  2002-06       Impact factor: 9.461

8.  Random screening of proteins for HLA-A*0201-binding nine-amino acid peptides is not sufficient for identifying CD8 T cell epitopes recognized in the context of HLA-A*0201.

Authors:  Christian Pelte; Georgy Cherepnev; Yanjun Wang; Constanze Schoenemann; Hans-Dieter Volk; Florian Kern
Journal:  J Immunol       Date:  2004-06-01       Impact factor: 5.422

9.  The HLA molecules DQA1*0501/B1*0201 and DQA1*0301/B1*0302 share an extensive overlap in peptide binding specificity.

Authors:  John Sidney; Marie-France del Guercio; Scott Southwood; Alessandro Sette
Journal:  J Immunol       Date:  2002-11-01       Impact factor: 5.422

10.  A correlation between the relative predisposition of MHC class II alleles to type 1 diabetes and the structure of their proteins.

Authors:  F Cucca; R Lampis; M Congia; E Angius; S Nutland; S C Bain; A H Barnett; J A Todd
Journal:  Hum Mol Genet       Date:  2001-09-15       Impact factor: 6.150

View more
  5 in total

1.  Immunotherapy for the prevention and treatment of type 1 diabetes: optimizing the path from bench to bedside.

Authors:  Damien Bresson; Matthias von Herrath
Journal:  Diabetes Care       Date:  2009-10       Impact factor: 17.152

Review 2.  Mechanisms of lymphatic system-specific viral replication and its potential role in autoimmune disease.

Authors:  S-K Friedrich; P A Lang; J Friebus-Kardash; V Duhan; J Bezgovsek; K S Lang
Journal:  Clin Exp Immunol       Date:  2019-01       Impact factor: 4.330

3.  Immunotherapeutic potential of the immunodominant T-cell epitope of lipocalin allergen Bos d 2 and its analogues.

Authors:  Soili A Saarelainen; Tuure T Kinnunen; Cécile Buhot; Ale T O Närvänen; Anu K Kauppinen; Marja A Rytkönen-Nissinen; Bernard Maillere; Tuomas I Virtanen
Journal:  Immunology       Date:  2007-10-16       Impact factor: 7.397

Review 4.  Genetic and Environmental Interaction in Type 1 Diabetes: a Relationship Between Genetic Risk Alleles and Molecular Traits of Enterovirus Infection?

Authors:  Marfa Blanter; Helena Sork; Soile Tuomela; Malin Flodström-Tullberg
Journal:  Curr Diab Rep       Date:  2019-08-10       Impact factor: 4.810

5.  Genetics of Autoimmune Thyroiditis in Type 1 Diabetes Reveals a Novel Association With DPB1*0201: Data From the Type 1 Diabetes Genetics Consortium.

Authors:  Heinrich Kahles; Pamela R Fain; Peter Baker; George Eisenbarth; Klaus Badenhoop
Journal:  Diabetes Care       Date:  2015-10       Impact factor: 19.112

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.